Order Article Reprints

Jeannerat A, Peneveyre C, Jaccoud S, Philippe V, Scaletta C, Hirt-Burri N, Abdel-Sayed P, Martin R, Applegate LA, Pioletti DP, et al. Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and Functional Optimization within a Cell Spheroid Formulation Process. Pharmaceutics. 2024; 16(10):1274. https://doi.org/10.3390/pharmaceutics16101274

Jeannerat, Annick, Cédric Peneveyre, Sandra Jaccoud, Virginie Philippe, Corinne Scaletta, Nathalie Hirt-Burri, Philippe Abdel-Sayed, Robin Martin, Lee Ann Applegate, Dominique P. Pioletti, and et al. 2024. "Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and Functional Optimization within a Cell Spheroid Formulation Process" Pharmaceutics 16, no. 10: 1274. https://doi.org/10.3390/pharmaceutics16101274

Jeannerat, A., Peneveyre, C., Jaccoud, S., Philippe, V., Scaletta, C., Hirt-Burri, N., Abdel-Sayed, P., Martin, R., Applegate, L. A., Pioletti, D. P., & Laurent, A. (2024). Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and Functional Optimization within a Cell Spheroid Formulation Process. Pharmaceutics, 16(10), 1274. https://doi.org/10.3390/pharmaceutics16101274